Real-World Studies
Chemotherapy Dose Intensity and FI-Lab Frailty Predict Colon Cancer Survival
Ağaoğlu et alCancer Chemotherapy and Pharmacology

In a retrospective cohort study of 94 patients aged 65 years and older with high-risk stage II or stage III colon cancer undergoing adjuvant chemotherapy after curative resection, investigators evaluated the prognostic value of frailty indices and chemotherapy dose intensity on clinical outcomes. Frailty was measured using the laboratory-based Frailty Index (FI-Lab) with a predefined threshold of 0.25, alongside the G8 geriatric screening tool, the modified 5-item Frailty Index (mFI-5), and the Charlson Comorbidity Index (CCI).
Over a median follow-up of 70 months, 28 recurrences (29.8%) and 22 deaths (23.4%) were observed. FI-Lab scores of 0.25 or higher independently predicted worse overall survival (HR: 3.73; p = 0.023) and disease-free survival (HR: 2.81; p = 0.029), while G8, mFI-5, and CCI showed no independent associations with survival. Chemotherapy dose initiation strategy also served as an independent predictor of outcomes: failure to initiate treatment at the optimal dose was linked to inferior overall survival (HR: 14.41; p = 0.011) and disease-free survival (HR: 5.16; p = 0.013) relative to completing the optimal dose. Conversely, dose reductions occurring after optimal initiation were not associated with survival decrements, supporting treatment approaches that factor in biological reserve and prioritize early treatment intensity.
Key Takeaways
- A laboratory-based Frailty Index (FI-Lab) ≥ 0.25 independently predicted inferior overall survival (HR: 3.73; p = 0.023) and disease-free survival (HR: 2.81; p = 0.029), whereas G8, mFI-5, and CCI were not independently associated with survival.
- Patients who did not start adjuvant chemotherapy at the optimal dose experienced worse overall survival (HR: 14.41; p = 0.011) and disease-free survival (HR: 5.16; p = 0.013) compared with those completing optimal dosing, whereas dose reduction following optimal initiation was not associated with survival.
Read the original sourceCancer Chemotherapy and Pharmacology
